INTERNATIONAL JOURNAL OF RESEARCH, EXPLORATION & KNOWLEDGE (IJREK)
Official Scholarly Journal Portal: **https://www.ijrek.org** | DOI: **https://doi.org/10.5281/zenodo.23741539**

EARLY CANCER DETECTION USING AI

Mr. Kate P.S[1], Kate Payal[2]

[1] Faculty Guide & Supervisor | [2] Dattakala Group Of Institutions Swami–Chincholi, Tal. Daund, Dist. Pune, India

Corresponding author: **payalkate88@gmail.com**

ARTICLE ID	ARTICLE TYPE	RESEARCH AREA	PUBLICATION
IJREK-2026-00169	Research Article	Computer Science	Volume 1, Issue Issue 1 (2026)
RECEIVED	**REVISED**	**ACCEPTED**	**PUBLISHED**
26 October 2026	11 November 2026	28 October 2026	11 November 2026

Abstract

Cancer remains a major global health challenge, and outcomes are often improved when disease is identified at an early stage. Artificial intelligence (AI) can support screening and clinical decision-making by analysing medical images, pathology slides, laboratory measurements, and structured clinical records. This paper reviews a conceptual framework for AI-assisted early cancer detection, focusing on data preparation, model development, clinical validation, explainability, and safe integration into healthcare workflows. It outlines how machine-learning and deep-learning methods may help identify suspicious patterns and prioritize cases for expert review. The proposed workflow emphasizes that AI output is decision support rather than a replacement for qualified clinicians. Data quality, population representativeness, privacy, bias, and external validation are treated as core requirements. The paper also presents an evaluation plan using sensitivity, specificity, precision, F1-score, calibration, and subgroup analysis. No clinical trial or original patient-data experiment is claimed; the framework is intended as a structured basis for future implementation and validation.

Keywords: *Artificial intelligence; early cancer detection; machine learning; medical imaging; clinical decision support; explainable A*

2. BACKGROUND AND RELATED WORK

Computer-aided diagnosis has developed from handcrafted image features and conventional classifiers toward deep neural networks that learn features directly from data. Convolutional neural networks (CNNs) are widely studied for image-based tasks, while transformer architectures and multimodal approaches are being explored for combining imaging with clinical context. In screening, an AI model may act as a triage aid, a second reader, or a quality-control tool. These roles are not interchangeable and require separate validation. 2.1 AI approaches Supervised learning: learns from labelled examples, such as images classified by a clinical reference standard. Deep learning: can identify complex spatial patterns in radiology, dermatology, endoscopy, or histopathology images. Risk modelling: uses structured variables such as age, family history, or laboratory results to estimate risk. Multimodal learning: combines imaging and clinical data when justified and securely available.

2.2 EVIDENCE AND LIMITATIONS

Table 1. AI approaches and practical considerations

Approach	Potential contribution	Key limitation
CNN / vision model	Detects visual patterns in scans or tissue images	May learn site-specific artifacts
Clinical risk model	Combines structured risk factors	Depends on data completeness and calibration
Multimodal model	Combines image and clinical context	Higher integration and privacy complexity
Human–AI review	Prioritizes cases for expert review	Needs workflow and usability validation

3. PROBLEM STATEMENT

The central problem is how to design an AI-assisted system that can help flag potentially suspicious findings early while maintaining clinical safety, fairness, privacy, and understandable outputs. The system must avoid presenting predictions as definitive diagnoses and should direct uncertain or high-risk cases to qualified professionals.

4. OBJECTIVES AND SCOPE

The main objective is to define a reliable framework for evaluating AI as an aid to early cancer detection. Specific objectives are to: (i) describe a pipeline for collecting and preparing authorized data; (ii) select an appropriate model for a clearly defined cancer-detection task; (iii) assess performance using clinically meaningful metrics; (iv) include explanation and uncertainty information where technically appropriate; and (v) establish safeguards for privacy, bias, and clinician oversight. The proposed scope is a research prototype using appropriately de-identified, permissioned data. It does not provide individual medical advice, replace diagnostic tests, or independently determine treatment. A specific cancer type and modality must be selected before implementation because screening pathways and reference standards differ by disease.

5. PROPOSED SYSTEM

The system is organized as a sequence of data governance, preprocessing, model inference, risk communication, and clinician review. Input could be a medical image or structured record depending on the selected use case. Data are checked for format, missing values, duplicates, image quality, and label consistency. A trained model generates a score or category; a separate decision layer applies a pre-defined threshold and flags uncertain cases. The output is shown with a concise explanation and the limitations of the model.

1. AUTHORIZED DATA SOURCE

De-identified images / approved clinical variables ↓ 2. Data Quality & Preprocessing Quality checks • normalization • label review • split by patient/site ↓

3. AI MODEL INFERENCE

Model score + uncertainty / out-of-distribution check ↓

4. RISK COMMUNICATION LAYER

Flag for review • explainable evidence • limitations shown ↓ 5. Clinician Review & Follow-up Qualified professional decides next diagnostic step




Figure 1. Proposed AI-assisted detection workflow with clinician oversight

6.3 PREPROCESSING AND TRAINING

Table 2. Methodology stages and quality gates

Stage	Deliverable	Quality control
Task definition	Protocol and target outcome	Clinical review of intended use
Dataset preparation	Versioned, governed dataset	Patient-level split and label audit
Model training	Reproducible model artifact	Fixed seeds and recorded configuration
Validation	Metrics and error analysis	External and subgroup checks
Prototype review	Human-readable output	Usability, privacy, and safety review

7. EVALUATION FRAMEWORK

Table 3. Evaluation metrics and their interpretation

Metric	What it indicates	Why it matters
Sensitivity	Share of positive cases detected	Important when missed disease is a major concern
Specificity	Share of negative cases correctly cleared	Helps estimate unnecessary follow-up burden
Precision / PPV	Share of positive alerts that are correct	Communicates the likely usefulness of an alert
ROC-AUC / PR-AUC	Ranking discrimination across thresholds	Useful for comparing models; not a substitute for calibration
Calibration	Agreement between predicted risk and observed outcomes	Important if scores are interpreted as probabilities
Subgroup performance	Metrics across relevant populations	Can reveal uneven performance or access concerns

8. SAFETY, ETHICS, AND PRIVACY

Healthcare AI introduces risks that extend beyond model accuracy. False negatives may delay further investigation, while false positives may cause anxiety, additional testing, and unnecessary costs. The interface should communicate that an AI flag is not a diagnosis and should provide a clear route for human review. Clinical responsibility remains with qualified professionals.

8.1 BIAS AND REPRESENTATIVENESS

Training data may underrepresent groups by age, sex, geography, skin tone, scanner type, or healthcare access. The development team should assess data coverage, document limitations, and report performance across clinically relevant subgroups where sample sizes permit. If a subgroup has insufficient evidence, the system should disclose that limitation rather than imply equivalent reliability.

8.2 EXPLAINABILITY AND UNCERTAINTY

Visual explanations or feature attributions can help reviewers inspect model behaviour, but they do not prove that a prediction is correct or that the model reasons clinically. Explanations should be evaluated with domain experts and presented as supporting information. The system should flag low-quality inputs, unfamiliar data, and uncertain predictions for manual review instead of forcing a confident classification.

8.3 SECURITY AND PRIVACY

Table 4. Main risks and mitigation measures

Risk	Possible consequence	Mitigation
False negative	Missed or delayed follow-up	Prioritize sensitivity where appropriate; human review
False positive	Unnecessary tests and anxiety	Threshold evaluation and clear communication
Dataset bias	Unequal performance	Representative data and subgroup evaluation
Data leakage	Overestimated results	Patient-level splits and independent testing
Privacy breach	Exposure of sensitive records	Access control, encryption, audit trail

9. IMPLEMENTATION AND DEPLOYMENT CONSIDERATIONS

Table 5. Suggested prototype components

Component	Responsibility	Example output
Data intake	Validate format and authorization	Accepted / rejected input
Preprocessing	Quality and format checks	Model-ready representation
Inference service	Run approved model version	Score and uncertainty
Review interface	Display result and limitations	Flag for clinician assessment
Monitoring	Track drift, errors, and usage	Periodic review report

11. CONCLUSION AND FUTURE SCOPE

This paper presented a conceptual framework for early cancer detection using AI, covering data governance, preprocessing, model inference, evaluation, clinician review, and post-deployment monitoring. AI may help identify suspicious patterns and prioritize cases, but it cannot independently establish a diagnosis. Reliable use requires representative data, external validation, explainable communication, privacy protections, and clear clinical accountability. Future work should select one cancer type and modality, obtain approved datasets, implement a baseline model, compare it with an appropriate reference standard, and conduct independent validation before considering clinical deployment.

REFERENCES

[1] World Health Organization, “Cancer,” WHO Fact Sheets. Available: https://www.who.int/news-room/fact-sheets/detail/cancer

[2] National Cancer Institute, “Cancer Screening Overview,” NCI. Available: https://www.cancer.gov/about-cancer/screening

[3] World Health Organization, Ethics and Governance of Artificial Intelligence for Health: WHO Guidance. Geneva: WHO, 2021.

[4] A. Esteva et al., “A guide to deep learning in healthcare,” Nature Medicine, vol. 25, pp. 24–29, 2019.

[5] A. Rajkomar, J. Dean, and I. Kohane, “Machine learning in medicine,” New England Journal of Medicine, vol. 380, pp. 1347–1358, 2019.

[6] World Health Organization, Regulatory Considerations on Artificial Intelligence for Health. Geneva: WHO, 2023.

[7] FDA, “Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices,” U.S. Food and Drug Administration. Available: https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices Note: References provide background resources. This paper proposes a research framework and does not claim original clinical findings.

Publication archival note: Official scholarly contribution published under CC BY 4.0 International License. Permanent record on **https://www.ijrek.org** | Article ID: IJREK-2026-00169